DMKJ
PTHS

David M. Knott Jr’s Pelthos Therapeutics PTHS Stock Holding History

David M. Knott Jr’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Buy
22,073
+1,000
+5% +$25.7K 0.33% 41
2026
Q1 		$443K Buy
21,073
+1,792
+9% +$42.5K 0.26% 48
2025
Q4 		$598K Buy
19,281
+13,169
+215% +$380K 0.28% 46
2025
Q3 		$171K Buy
+6,112
New +$148K 0.07% 64

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

David M. Knott Jr's PTHS Position: Q2 2026 in Review

David M. Knott Jr increased its Pelthos Therapeutics (PTHS) stake by 4.7% in Q2 2026, buying an estimated $25.7K and bringing the position to 22,073 shares worth $624K. The position accounts for 0.33% of the portfolio, ranked #41.

David M. Knott Jr first reported a position in PTHS in Q3 2025 and has held it in 4 quarters since. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • David M. Knott Jr held 22,073 shares of Pelthos Therapeutics worth $624K as of Q2 2026.
  • David M. Knott Jr bought 1,000 Pelthos Therapeutics shares in Q2 2026, an estimated $25.7K.
  • Pelthos Therapeutics made up 0.33% of David M. Knott Jr's portfolio in Q2 2026, its #41 holding.
  • David M. Knott Jr first reported a position in Pelthos Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on David M. Knott Jr's 13F filing for Q2 2026, filed 12 Aug 2026.